Amgen’s Strategic Shift to New Drugs Offsets Patent Cliff Pressures

Key Facts

1Newer drugs and biosimilars now constitute 70% of Amgen's total sales.

2Amgen's growth portfolio grew by 24% year-over-year in the most recent quarter.

As major biotech firms pivot to safeguard revenue against patent cliffs, Amgen has successfully transitioned its business model toward next-generation therapies. According to analyst reports, newer drugs and biosimilars now constitute 70% of the company's total sales mix. This strategic growth portfolio expanded by 24% year-over-year in the most recent quarter, effectively neutralizing the revenue declines observed in legacy blockbuster medications that have lost patent protection.

This transition occurs as the broader pharmaceutical sector faces intensifying pricing pressures, with peers like Pfizer and Gilead Sciences also racing to diversify their pipelines. Compared to industry benchmarks, Amgen’s focus on the rapidly expanding biosimilars market has provided a competitive edge in maintaining operational margins. Per market data, the company’s ability to scale its new product launches has been a key differentiator in sustaining long-term fundamental value despite the loss of exclusivity on older brands.

In the equity markets, AMGN shares stood at $341.66 (close June 17, 2026), having touched a session high of $349.4. Traders are monitoring support levels near the recent low of $338.9 to gauge near-term momentum. While the upcoming economic calendar shows no direct corporate catalysts, broader market sentiment remains influenced by recent data such as the Michigan Consumer Sentiment index, which printed at 48.9 on June 12, reflecting the complex macroeconomic environment for healthcare spending.